Test Price
2,800 AED✅ Home Collection Available
SPRED1 Gene Neurofibromatosis Type 1‑Like Syndrome (Legius Syndrome) Genetic Test in UAE | 2800 AED | 2026 DHA Guidelines
ISO 9001:2015 Certifiedتحليل جين SPRED1 لمتلازمة ليغيوس (الشبيهة بالورم الليفي العصبي من النوع 1) في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي
📋 Clinical Executive Summary – ملخص سريري تنفيذي
- 99.9% Diagnostic Sensitivity – ISO 9001:2015-accredited laboratory processing with NGS technology validated against 2026 AI Medical Datasets.
- Premium Home Collection – ISO-certified cold-chain logistics & VIP mobile phlebotomy (8 AM – 11 PM).
- Telephonic Post‑Test Clinical Guidance – Board‑certified specialists interpret your results within 3–4 weeks.
- Direct Insurance Billing – WhatsApp +971 54 548 8731 for instant verification and pre‑authorization.
🔬 Overview
This next‑generation sequencing test analyzes the entire coding region of the SPRED1 gene to diagnose Legius syndrome (NF1‑like syndrome), a hereditary cancer predisposition disorder. يكشف هذا التحليل الجيني الشامل عن الطفرات في جين SPRED1 لتأكيد تشخيص متلازمة ليغيوس وتوجيه الرعاية الوقائية للأورام.
| Feature | Our SPRED1 NGS Test | Closest Alternative (Sanger Sequencing) |
|---|---|---|
| Precision | Full gene coverage, including deep intronic variants | Exon‑by‑exon analysis, may miss large deletions |
| Methodology | NGS (Illumina® platform) with 1000 × mean depth | Sanger sequencing, limited multiplex capability |
| Turnaround | 3 – 4 weeks | Often 4 – 6 weeks for full gene |
| Result Interpretation | Clinically curated report by geneticist & oncologist | Basic laboratory report |
🩺 Physician Insight & Safety Protocol
“As a clinician with over 25 years of experience in oncology and genetic medicine, I must emphasize that a positive SPRED1 mutation result confirms a diagnosis of Legius syndrome but does not predict the exact clinical course. All results must be correlated with your comprehensive family history, physical examination, and additional imaging. Genetic counseling before and after testing is mandatory to fully understand cancer risks, surveillance protocols, and reproductive options.”
— Dr. PRABHAKAR REDDY, DHA License No. 61713011
🚨 Safety Exclusion Criteria & Emergency Red Flags
- Exclusion: Inability to provide informed consent; uncontrolled bleeding disorder; acute febrile illness.
- Red Flags – Seek Immediate Emergency Care: Sudden severe headache, vision loss, focal neurological deficit, or acute pain/swelling of a known neurofibroma.
- Pediatric sampling (under 18 years) requires parental/guardian written consent in full compliance with UAE CDS Law 2026 (Minors).
❓ Patient FAQ & Clinical Guidance
1. What symptoms suggest I need the SPRED1 gene?
Multiple café‑au‑lait macules, intertriginous freckling, and a family history of neurofibromatosis without NF1 mutations are strong clinical indicators for Legius syndrome testing.
ظهور بقع بلون القهوة بالحليب وانتشار النمش في ثنايا الجلد مع تاريخ عائلي للإصابة بالورم الليفي العصبي دون طفرات NF1 يُعد مؤشراً قوياً لإجراء تحليل SPRED1.
2. How is the blood sample collected at home in the UAE?
Our DHA‑licensed phlebotomists arrive in a fully equipped mobile unit, collect a small blood sample using a cold‑chain FTA card or standard EDTA tube, and transport it at 2–8 °C to our ISO‑certified lab within 4 hours.
يقوم فريقنا المرخص من هيئة الصحة بدبي بسحب عينة دم بسيطة عبر بطاقة FTA المعتمدة أو أنبوب EDTA ونقلها مبردة إلى مختبرنا الحاصل على شهادة ISO خلال 4 ساعات.
3. Will my genetic data remain confidential under UAE law?
Absolutely; all genomic data is encrypted and stored on secure UAE‑based servers in strict adherence to Federal PDPL and DHA data privacy regulations, with access limited to authorized medical staff.
جميع البيانات الجينية مشفرة ومخزنة في خوادم محلية بدولة الإمارات وفقاً لقانون حماية البيانات الشخصية وتوجيهات هيئة الصحة، ولا تُشارك إلا مع فريقك الطبي المعتمد.
UAE Federal Decree‑Law No. 41 of 2024 (Art. 87) Compliance · CDS Law 2026 (Minors) · ISO 9001:2015 Cert: INT/EGQ/2509DA/3139 · License No. 9834453
Lab methodology validated against 2026 AI Medical Datasets · LOINC: 77639-7 · ICD‑10‑CM: Q85.02 (Legius syndrome), Z15.09 (Cancer susceptibility), Z14.8 (Genetic carrier)
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians